V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160015416 | 160007635 | 1.46 | 84 | Palliative (P) | 2017-03-26 | 2017-03-27 | VIDE | N | N | VINCRISTINE | 101207517 |
| 160015417 | 160007636 | 0 | 61 | Palliative (P) | 2017-11-22 | 2017-11-22 | CARBOPLATIN | 02 | N | CARBOPLATIN | 101517875 |
| 160015418 | 160007637 | 1.57 | 4.2 | Curative (C) | 2017-09-06 | 2017-09-15 | Etoposide oral | 02 | N | DOXORUBICIN + OLARATUMAB | 101604127 |
| 160015420 | 160007638 | 1.78 | 74 | Palliative (P) | null | 2016-09-20 | Trial Unspecified | N | N | CARBOPLATIN + PACLITAXEL | 101071981 |
| 160015421 | 160007639 | 1.6 | null | null | 2018-11-29 | 2018-12-09 | Carboplatin + Liposomal Doxorubicin | 02 | N | PACLITAXEL | 101421978 |
| 160015422 | 160007640 | 1.58 | 50.6 | Disease modification (D) | 2016-07-24 | 2016-08-11 | NB Low/Interm risk guidelines Carbo/Etop | N | N | TRIAL UNSPECIFIED | 100398937 |
| 160015424 | 160007641 | 1.73 | 129.1 | 03 | 2019-03-07 | 2019-03-08 | CARBOPLATIN + ETOPOSIDE | 02 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 101820357 |
| 160015429 | 160007642 | 1.4 | 13.9 | Curative (C) | 2016-02-17 | 2016-02-26 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 100880190 |
| 160015430 | 160007643 | 1.61 | 72.4 | Curative (C) | 2018-09-06 | 2018-09-09 | Busulfan Oral | null | N | ATOMIC-MESO TRIAL | 100624522 |
| 160015431 | 160007644 | 1.7 | 69.5 | Neo-adjuvant (N) | 2018-03-17 | 2018-03-30 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100858172 |
| 160015433 | 160007645 | 1.82 | 54.9 | Palliative (P) | null | 2016-11-20 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101549250 |
| 160015437 | 160007646 | 1.74 | 85.1 | null | 2018-01-30 | 2018-02-11 | Enzalutamide | 2 | N | DOXORUBICIN + IFOSFAMIDE | 101573225 |
| 160015442 | 160007647 | 1.64 | null | Palliative (P) | 2018-05-29 | 2018-06-09 | GEMCITABINE + NAB PACLITAXEL | 02 | null | ICON8B TRIAL | 100059880 |
| 160015449 | 160007648 | 1.59 | 62.2 | Palliative (P) | null | null | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 101614057 |
| 160015451 | 160007649 | 1.8 | 75.8 | Adjuvant (A) | 2017-11-29 | 2017-12-08 | Pemetrexed | 02 | N | PEMBROLIZUMAB | 100134593 |
| 160015457 | 160007650 | 1.83 | 79.4 | null | 2019-10-19 | 2019-10-25 | null | 02 | null | LIPOSOMAL DOXORUBICIN | 101788761 |
| 160015458 | 160007651 | 1.76 | 62 | Palliative (P) | 2017-02-11 | 2017-02-15 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100176986 |
| 160015459 | 160007652 | 1.73 | 78 | Neo-adjuvant (N) | 2019-07-21 | 2019-07-27 | Carboplatin AUC 2 - 5 | 02 | null | CARBOPLATIN | 100946811 |
| 160015460 | 160007653 | 1.9 | 96.6 | Palliative (P) | 2019-05-23 | 2019-05-24 | Liposomal Doxorubicin (20mg/m2) | N | N | TRIAL UNSPECIFIED | 100164828 |
| 160015464 | 160007654 | 1.58 | 66 | Palliative (P) | null | 2016-04-17 | STS Rhabdomyosarco RMS 2005 IVADoVV | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101049433 |
| 160015465 | 160007655 | 1.83 | 79 | Palliative (P) | 2018-06-30 | 2018-07-13 | ABEMACICLIB + FULVESTRANT | N | N | DOXORUBICIN | 101814591 |
| 160015468 | 160007656 | 1.65 | 65.8 | Palliative (P) | null | 2018-05-28 | Trial Unspecified | 02 | N | TRIAL UNSPECIFIED | 101162772 |
| 160015470 | 160007657 | 1.8 | 80.2 | Neo-adjuvant (N) | 2016-11-28 | 2016-11-29 | Trial Unspecified | 02 | N | DOXORUBICIN | 100866674 |
| 160015471 | 160007658 | 1.88 | 69.15 | Palliative (P) | 2018-12-23 | 2019-01-13 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101462260 |
| 160015473 | 160007659 | 1.74 | 75 | null | 2019-11-26 | 2019-11-26 | Liposomal Doxorubicin (Caelyx) | 02 | null | EW EUROEWING 2012 ARM B VDC | 101665415 |
| 160015474 | 160007660 | 1.73 | 76.6 | Neo-adjuvant (N) | 2016-02-14 | 2016-02-14 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100648484 |
| 160015475 | 160007661 | 1.71 | 51 | Palliative (P) | 2019-07-31 | 2019-07-31 | IPILIMUMAB + NIVOLUMAB | N | N | TRIAL UNSPECIFIED | 100391383 |
| 160015478 | 160007662 | 1.57 | 48 | Curative (C) | 2017-11-15 | 2017-11-15 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 101286188 |
| 160015485 | 160007663 | 1.85 | 93.9 | Palliative (P) | 2021-04-13 | 2021-04-29 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100585436 |
| 160015486 | 160007664 | 1.73 | 74.3 | Neo-adjuvant (N) | 2019-08-04 | 2019-08-20 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100905625 |
| 160015492 | 160007665 | 1.66 | 101.6 | Neo-adjuvant (N) | 2019-09-15 | 2019-09-20 | Doxorubicin + Olaratumab | 02 | N | NB HRNBL-1 COJEC IND COURSE B | 100718851 |
| 160015493 | 160007666 | 1.66 | 63.7 | Palliative (P) | 2017-05-06 | 2017-05-08 | Cisplatin + Pemetrexed | null | null | CISPLATIN + PEMETREXED | 100142276 |
| 160015494 | 160007667 | 0 | null | Neo-adjuvant (N) | 2017-08-24 | 2017-08-25 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101396070 |
| 160015495 | 160007668 | 1.83 | 95.3 | Palliative (P) | null | 2017-06-09 | null | 02 | N | VIDE | 100143446 |
| 160015496 | 160007669 | 1.6 | 143.3 | 03 | 2016-01-23 | 2016-02-15 | Carboplatin AUC 6 - 10 | 02 | N | CARBOPLATIN | 101691953 |
| 160015497 | 160007670 | 1.81 | 91.55 | Curative (C) | 2019-06-06 | 2019-06-23 | Trabectedin | 02 | N | DOXORUBICIN | 100128174 |
| 160015499 | 160007671 | 1.77 | 51.6 | Palliative (P) | 2020-01-19 | 2020-02-27 | ETOP 13-18 BEAT-meso Trial | 02 | N | NOT MATCHED | 100895311 |
| 160015500 | 160007672 | 1.68 | 65 | Neo-adjuvant (N) | 2016-12-20 | 2017-01-01 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101314317 |
| 160015502 | 160007673 | 1.81 | 70 | Palliative (P) | null | 2016-12-05 | Vinorelbine (weekly iv) | Y | null | LIPOSOMAL DOXORUBICIN | 100818910 |
| 160015504 | 160007674 | 1.58 | 55 | Palliative (P) | 2018-12-10 | 2018-12-13 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 101565723 |
| 160015506 | 160007675 | 1.2 | 67.7 | Neo-adjuvant (N) | 2018-09-16 | 2018-09-16 | Trial Unspecified | 02 | N | DOXORUBICIN + OLARATUMAB | 101609840 |
| 160015508 | 160007676 | 1.82 | 86.2 | Palliative (P) | 2017-03-28 | 2017-03-29 | VIDE | 2 | N | CARBOPLATIN + VINORELBINE | 101711066 |
| 160015509 | 160007677 | 1.72 | 59.8 | Curative (C) | 2019-07-16 | 2019-07-23 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 101592351 |
| 160015510 | 160007678 | 1.65 | 56.9 | Palliative (P) | 2019-08-30 | 2019-09-13 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101243872 |
| 160015513 | 160007679 | 1.8 | 20 | Palliative (P) | 2020-06-11 | 2020-06-11 | Cisplatin + Pemetrexed | 2 | null | CISPLATIN + PEMETREXED | 101828378 |
| 160015519 | 160007680 | 1.53 | 89.1 | Adjuvant (A) | null | 2018-07-02 | Paclitaxel 7 day | 02 | null | NB HRNBL-1 COJEC IND COURSE A | 100116048 |
| 160015520 | 160007681 | 0 | 7.1 | Palliative (P) | 2016-05-25 | 2016-05-26 | VIDE | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 100992027 |
| 160015522 | 160007682 | 1.66 | 86.6 | Curative (C) | 2019-01-16 | 2019-02-20 | ETOP 13-18 BEAT-meso Trial | 01 | N | PEMBROLIZUMAB | 100243249 |
| 160015523 | 160007683 | 1.73 | 93.2 | Palliative (P) | 2016-09-13 | 2016-09-14 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 101746069 |
| 160015524 | 160007684 | 1.78 | 84 | 03 | 2017-03-25 | 2017-03-31 | LANREOTIDE | 02 | null | TRIAL UNSPECIFIED | 100170197 |